Clinical trials: Bipolar Disorder, Manic
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
- Trial name
- NCT00257166
- Testing
- Ziprasidone oral capsules
- Where
- 50 sites in United States
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder
Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes
The primary objective of this study is to compare the efficacy and tolerability of quetiapine versus divalproex extended-release administered in a rapid oral loading fashion in the treatment of acute episodes of mania or mixed…
- Trial name
- NCT00397020
- Testing
- divalproex ER, quetiapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Bipolar I Disorder, Schizophrenia
Study in Adolescents With Schizophrenia or Bipolar Disorder
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
- Trial name
- NCT00982020
- Testing
- Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
- Where
- 14 sites in United States, Poland and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
Decision-Making in Bipolar Disorder
Forty subjects with bipolar disorder who are not receiving a mood-stabilizing medication for the treatment of their illness will participate in this study.
- Trial name
- NCT01463111
- Testing
- Lithium, Valproate, Lamotrigine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Emory University
Bipolar Disorder
Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?
This study will evaluate the relative effectiveness of risperidone Consta injections occurring every 2 weeks in contrast to treatment as usual in preventing symptomatic relapse and rates of rehospitalization or admission into…
- Trial name
- Consta (NCT00571688)
- Testing
- Risperdal (risperidone) Consta, Treatment as usual
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University
Bipolar Disorder
3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
3-week study to evaluate efficacy and safety of ziprasidone with either lithium or divalproex in acutely manic subjects
- Trial name
- NCT00312494
- Testing
- Ziprasidone
- Where
- 66 sites in United States
- Volunteers
- 680 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar I Disorder
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
The primary objective of this trial is to evaluate the clinical efficacy and safety of aripiprazole in comparison to placebo in patients with Bipolar I Disorder experiencing a manic or mixed episode.
- Trial name
- NCT00606281
- Testing
- Aripiprazole
- Where
- 12 sites in China, Japan and 2 more
- Volunteers
- 258 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder
Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents
This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
- Trial name
- TEAM (NCT00057681)
- Testing
- Lithium carbonate, Valproate, Risperidone
- Where
- 5 sites in United States
- Volunteers
- 379 people
- Sponsor
- Washington University School of Medicine
Bipolar I Disorder, Acute Mania
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
This study evaluated the safety and evaluate the safety and tolerability of open-label brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult subjects with bipolar I disorder.
- Trial name
- NCT03287869
- Testing
- Brexpiprazole
- Where
- 73 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
Efficacy of Aripiprazole in Combination with Lamotrigine in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients with Recent Manic or Mixed Episode
- Trial name
- NCT00277212
- Testing
- Lamotrigine + Aripiprazole
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 1,169 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mania (Neurotic)
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
This will be a 24-week, randomized, double-blind, placebo-controlled trial of adjunctive probiotic therapy in 66 persons hospitalized with a manic or mixed episode.
- Trial name
- NCT03383874
- Testing
- Probio-Tec BG-VCap-6.5
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Disorder, Schizoaffective Disorder
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study.
- Conditions
- Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania
- Trial name
- NCT00431184
- Testing
- Pentazocine, Lorazepam
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mclean Hospital
Bipolar Disorder, Schizoaffective Disorder
Probiotics to Prevent Relapse After Hospitalization for Mania
The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania.
- Trial name
- NCT01731171
- Testing
- Probiotic Supplement, Inert Compound
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System
Bipolar Disorder
40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
The primary objective of this trial was to characterize the long-term (up to 40 weeks) safety and tolerability of asenapine in bipolar I disorder subjects who had not completely responded to continuing treatment with lithium or…
- Trial name
- NCT00145509
- Testing
- Asenapine
- Volunteers
- 77 people
- Sponsor
- Organon and Co
Pediatric Bipolar Spectrum Disorders
Inositol and Omega-3 Fatty Acids in Pediatric Mania
The purpose of this study is to a) evaluate the efficacy of omega-3 fatty acids versus inositol in the treatment of pediatric bipolar disorder, b) evaluate the efficacy of omega-3 fatty acid plus inositol in the treatment of…
- Trial name
- NCT01396486
- Testing
- Omega-3, Inositol
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder
Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed)
- Trial name
- NCT00265330
- Testing
- Ziprasidone oral capsules
- Where
- 41 sites in United States
- Volunteers
- 169 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
This study will assess the effects of bipolar disorder on brain activity and will determine if medication changes the brain activity in people with bipolar disorder.
- Trial name
- NCT00596622
- Testing
- Lithium
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Indiana University
Bipolar Disorder, Mania
Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder
This is an 8-week open-label study aimed at assessing the effectiveness and tolerability of Quetiapine, in the treatment of preschool children aged 4 to 6 years with bipolar and bipolar spectrum disorder.
- Trial name
- NCT00181883
- Testing
- quetiapine
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Schizophrenia
Non Interventional Study In Bipolar Disorder And Schizophrenia With Zeldox
Investigation of the impact of Zeldox on metabolic parametres in patients with bipolar disorder or with schizophrenia and impact of the treatment for the quality of life
- Trial name
- NCT00538629
- Testing
- no intervention
- Volunteers
- 471 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.